Valor202020212022202320242025TTMGastos comerciales, generales y administrativos188.27 M567 M1.13 B1.75 B1.32 B1.15 B1.02 BInvestigación y desarrollo1.37 B1.99 B3.29 B4.84 B4.54 B3.13 B3.13 BBeneficio operativo-763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B-3.07 BTotal de ingresos no operativos-53.84 M-65 M124 M323 M381 M365 M365 MGastos por intereses, netos de intereses capitalizados9.89 M17 M29 M38 M24 M3 M—Ingresos no operativos, una vez deducidos los gastos por intereses-57.65 M-53 M140 M409 M444 M370 M373 MIngresos/gastos extraordinarios-6.08 M-29 M-45 M-124 M-87 M-8 M-8 MBeneficio antes de impuestos-744.51 M13.29 B9.57 B-3.94 B-3.61 B-2.77 B-2.77 BParticipación en los beneficios———-35 M-52 M-8 M-8 MImpuestos2.55 M1.08 B1.21 B772 M-46 M54 M54 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos——-28 M-7 M-60 M-77 M-77 MBeneficio neto antes de actividades interrumpidas-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-2.82 BOperaciones suspendidas———————Beneficio neto-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-2.82 BAjuste por dilución0——————Dividendos de las acciones preferentes0——————Beneficio neto diluido atribuible a los accionistas-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-2.82 BBeneficio básico por acción—30.3121.26-12.33-9.28-7.26-7.26Beneficio por acción diluido—28.2920.12-12.33-9.28-7.26-7.26Número medio de acciones ordinarias—403 M394 M382 M384 M389 M1.55 BAcciones diluidas—431 M416 M382 M384 M389 M1.55 BEBITDA-731.89 M13.53 B9.77 B-3.62 B-3.76 B-2.86 B-2.86 BEBIT-763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B-3.07 BCosto de los ingresos7.93 M2.62 B5.42 B4.69 B1.46 B868 M868 MOtros costes de producción——1.92 B2.34 B555 M315 M315 MAmortización y depreciación (flujo de caja)31.25 M232 M348 M617 M185 M211 M211 M
Moderna Inc
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.